Top

Journal of Orthopaedic Surgery and Research

Published in:

Open Access 01-12-2019 | osteosarcoma | Research article

Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma

Authors: Hongzeng Wu, Jinming Zhang, Ruoheng Dai, Jianfa Xu, Helin Feng

Published in: Journal of Orthopaedic Surgery and Research | Issue 1/2019

Abstract

Background

Osteosarcoma is aggressive and prognostic biomarkers are important to predict the outcomes of surgery and chemotherapy. Here, we investigated the potential of transferrin receptor-1 (TfR1) and vascular endothelial growth factor (VEGF) as prognostic markers of osteosarcoma.

Methods

TfR1 and VEGF in osteosarcoma samples from a cohort of 53 osteosarcoma patients were detected by immunohistochemistry analysis. The correlation of TfR1 and VEGF levels with clinicopathological parameters was analyzed by Pearson chi-square and Spearman-rho tests. Overall patient survival was analyzed by the Kaplan-Meier method.

Results

We found that TfR1 and VEGF expression levels were low in 20.8% and 18.9%; modest in 35.8% and 35.8%; and high in 43.4% and 45.3% of osteosarcoma patients, respectively. TfR1 and VEGF expression was significantly correlated to histologic grade, Enneking stage, and distant metastasis. TfR1 expression was significantly correlated to VEGF expression and both TfR1 expression and VEGF expression were correlated to shorter overall survival.

Conclusions

TfR1 and VEGF are potential prognostic factors for osteosarcoma.

Franchi A. Epidemiology and classification of bone tumors. Clin Cases Miner Bone Metab. 2012;9(2):92–5.PubMedPubMedCentral

Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev. 2014;40(4):523–32.PubMedCrossRef

Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 2015;44(12):547–53.

Patrascu JM, Vermesan D, Mioc ML, Lazureanu V, Florescu S, Tarullo A, Tatullo M, Abbinante A, Caprio M, Cagiano R, Haragus H. Musculo-skeletal tumors incidence and surgical treatment—a single center 5-year retrospective. Eur Rev Med Pharmacol Sci. 2014;18(24):3898–901.PubMed

Folpe AL, Lyles RH, Sprouse JT, Conrad EU 3rd, Eary JF. (F-18) fluorodeoxyglucose positron emission tomography as a predictor of pathologic grade and other prognostic variables in bone and soft tissue sarcoma. Clin Cancer Res. 2000;6(4):1279–87.PubMed

Torti SV, Torti FM. Ironing out cancer. Cancer Res. 2011;71(5):1511–4.PubMedPubMedCentralCrossRef

Arredondo M, Núñez MT. Iron and copper metabolism. Mol Aspects Med. 2005;26(4-5):313–27.PubMedCrossRef

Whitnall M, Howard J, Ponka P, Richardson DR. A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics. Proc Natl Acad Sci U S A. 2006;103(40):14901–6.PubMedPubMedCentralCrossRef

Xiong W, Wang L, Yu F. Regulation of cellular iron metabolism and its implications in lung cancer progression. Med Oncol. 2014;31(7):28.PubMedCrossRef

10.

Chanvorachote P, Luanpitpong S. Iron induces cancer stem cells and aggressive phenotypes in human lung cancer cells. Am J Physiol Cell Physiol. 2016;310(9):C728–39.PubMedCrossRef

11.

Zhang C, Zhang F. Iron homeostasis and tumorigenesis: molecular mechanisms and therapeutic opportunities. Protein Cell. 2015;6(2):88–100.PubMedCrossRef

12.

Daniels TR, Delgado T, Rodriguez JA, Helguera G, Penichet ML. The transferrin receptor part I: Biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 2006;121(2):144–58.PubMedCrossRef

13.

Rosager AM, Sørensen MD, Dahlrot RH, et al. Transferrin receptor-1 and ferritin heavy and light chains in astrocytic brain tumors: Expression and prognostic value. PLoS One. 2017;12(8):e0182954.PubMedPubMedCentralCrossRef

14.

Zhang B, Zhang Y, Zhang X, Lv Y. Suspension state promotes extravasation of breast tumor cells by increasing integrin β1 expression. Biocell. 2018;42:17–24.CrossRef

15.

Zhuang M, Peng Z, Wang J. Su X. Vascular endothelial growth factor gene polymorphisms and gastric cancer risk: a meta-analysis. J BUON. 2017;22(3):714–24.PubMed

16.

Huang CC, Michael CW, Pang JC. Fine needle aspiration of primary mediastinal synovial sarcoma: cytomorphologic, immunohistochemical, and molecular study. Diagn Cytopathol. 2014;42(2):170–6.PubMedCrossRef

17.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.CrossRefPubMed

18.

Yağcı-Küpeli B, Akyüz C, Yalçın B, Varan A, Kutluk T, Büyükpamukçu M. Single institution experience on cancer among adolescents 15-19 years of age. Turk J Pediatr. 2017;59(1):1–5.PubMedCrossRef

19.

Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med. 1988;319(16):1047–52.PubMedCrossRef

20.

Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer. 1994;56(3):364–9.PubMedCrossRef

21.

Knekt P, Reunanen A, Takkunen H, Aromaa A, Heliövaara M, Hakulinen T. Body iron stores and risk of cancer. Int J Cancer. 1994;56(3):379–82.PubMedCrossRef

22.

Richardson DR, Ponka P. The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells. Biochim Biophys Acta. 1997;1331(1):1–40.PubMedCrossRef

23.

Faulk WP, Hsi BL, Stevens PJ. Transferrin and transferrin receptors in carcinoma of the breast. Lancet. 1980;2(8191):390–2.PubMedCrossRef

24.

Habeshaw JA, Lister TA, Stansfeld AG, Greaves MF. Correlation of transferrin receptor expression with histological class and outcome in non-Hodgkin lymphoma. Lancet. 1983;1(8323):498–501.PubMedCrossRef

25.

Wrba F, Ritzinger E, Reiner A, Holzner JH. Transferrin receptor (TrfR) expression in breast carcinoma and its possible relationship to prognosis. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol. 1986;410(1):69–73.PubMedCrossRef

26.

Calzolari A, Oliviero I, Deaglio S, et al. Transferrin receptor 2 is frequently expressed in human cancer cell lines. Blood Cells Mol Dis. 2007;39(1):82–91.PubMedCrossRef

Title: Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma
Authors: Hongzeng Wu
Jinming Zhang
Ruoheng Dai
Jianfa Xu
Helin Feng
Publication date: 01-12-2019
Publisher: BioMed Central
Keywords: osteosarcoma
Metastasis
Osteosarcoma
Published in: Journal of Orthopaedic Surgery and Research / Issue 1/2019
Electronic ISSN: 1749-799X
DOI: https://doi.org/10.1186/s13018-019-1301-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Transferrin receptor-1 and VEGF are prognostic factors for osteosarcoma

Abstract

Background

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2019

A polyaxial fixation brace for the treatment of idiopathic congenital talipes equinovarus in newborns

Correlation of serum PTH level and fracture healing speed in elderly patients with hip fracture

The adductor tubercle can be a radiographic landmark for joint line position determination: an anatomic-radiographic correlation study

Anterior percutaneous full-endoscopic transcorporeal decompression of the spinal cord for single-segment cervical spondylotic myelopathy: The technical interpretation and 2 years of clinical follow-up

RETRACTED ARTICLE: Effect of sagittal femoral component alignment on biomechanics after mobile-bearing total knee arthroplasty

Comparative efficacy and safety of different hemostatic methods in total hip arthroplasty: a network meta-analysis